• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    7/24/23 1:31:03 PM ET
    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARMP alert in real time by email

    Gainers

    • Armata Pharmaceuticals (AMEX:ARMP) stock rose 42.2% to $1.64 during Monday's regular session. Trading volume for this security as of 13:30 EST is 2.1 million, which is 25226.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $59.0 million.
    • Etao International Co (NASDAQ:ETAO) stock increased by 35.66% to $0.64. As of 13:30 EST, this security is trading at a volume of 754.1K shares, making up 144.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $65.2 million.
    • Marker Therapeutics (NASDAQ:MRKR) shares moved upwards by 16.33% to $7.69. Marker Therapeutics's stock is trading at a volume of 862.4K shares as of 13:30 EST. This is 101.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $67.6 million.
    • Heron Therapeutics (NASDAQ:HRTX) shares increased by 15.57% to $1.59. Heron Therapeutics's stock is trading at a volume of 4.0 million shares as of 13:30 EST. This is 192.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $190.9 million.
    • Biocept (NASDAQ:BIOC) stock rose 15.5% to $1.49. Biocept's stock is trading at a volume of 442.3K shares as of 13:30 EST. This is 172.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares moved upwards by 13.23% to $0.58. As of 13:30 EST, NeuroBo Pharmaceuticals's stock is trading at a volume of 1.8 million, which is 460.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $15.8 million.

    Losers

    • Kodiak Sciences (NASDAQ:KOD) shares fell 46.4% to $3.9 during Monday's regular session. Kodiak Sciences's stock is trading at a volume of 16.9 million shares as of 13:30 EST. This is 2622.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $204.4 million.
    • BioCardia (NASDAQ:BCDA) stock fell 44.45% to $1.1. As of 13:30 EST, BioCardia's stock is trading at a volume of 1.0 million, which is 2231.7% of its average full-day volume over the last 100 days. The company's market cap stands at $22.4 million.
    • Infinity Pharmaceuticals (NASDAQ:INFI) stock fell 39.6% to $0.13. Trading volume for Infinity Pharmaceuticals's stock is 6.1 million as of 13:30 EST. This is 901.6% of its average full-day volume over the last 100 days. The company's market cap stands at $12.0 million.
    • Verrica Pharmaceuticals (NASDAQ:VRCA) stock fell 35.75% to $4.79. Verrica Pharmaceuticals's stock is trading at a volume of 2.4 million shares as of 13:30 EST. This is 994.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $200.4 million.
    • ViewRay (NASDAQ:VRAY) stock decreased by 28.65% to $0.04. As of 13:30 EST, ViewRay's stock is trading at a volume of 58.4 million, which is 507.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $7.7 million.
    • Evelo Biosciences (NASDAQ:EVLO) stock fell 26.79% to $8.5. As of 13:30 EST, Evelo Biosciences's stock is trading at a volume of 1.3 million, which is 143.1% of its average full-day volume over the last 100 days. The company's market cap stands at $159.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ARMP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARMP
    $BCDA
    $BIOC
    $ETAO

    CompanyDatePrice TargetRatingAnalyst
    Kodiak Sciences Inc
    $KOD
    11/11/2025$24.00Neutral → Buy
    H.C. Wainwright
    Kodiak Sciences Inc
    $KOD
    10/24/2025$24.00Neutral → Overweight
    Analyst
    Kodiak Sciences Inc
    $KOD
    9/25/2025$17.00Underweight → Equal Weight
    Barclays
    Kodiak Sciences Inc
    $KOD
    9/22/2025$15.00Buy
    Jefferies
    Kodiak Sciences Inc
    $KOD
    8/14/2025$15.00Underweight → Neutral
    Analyst
    Heron Therapeutics Inc.
    $HRTX
    6/9/2025$6.00Buy
    H.C. Wainwright
    Marker Therapeutics Inc.
    $MRKR
    3/5/2025$8.00Buy
    Canaccord Genuity
    Kodiak Sciences Inc
    $KOD
    12/9/2024$20.00Hold → Buy
    Jefferies
    More analyst ratings

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Altman Peter bought $5,650 worth of shares (5,000 units at $1.13), increasing direct ownership by 2% to 273,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    2/4/26 5:47:41 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President and CEO Altman Peter bought $1,194 worth of shares (900 units at $1.33), increasing direct ownership by 0.34% to 268,866 units (SEC Form 4)

    4 - BioCardia, Inc. (0000925741) (Issuer)

    1/21/26 5:03:15 PM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $60,000,008 worth of shares (2,608,696 units at $23.00) (SEC Form 4)

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    12/19/25 4:06:09 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kodiak Sciences upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Kodiak Sciences from Neutral to Buy and set a new price target of $24.00

    11/11/25 8:00:12 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Analyst with a new price target

    Analyst upgraded Kodiak Sciences from Neutral to Overweight and set a new price target of $24.00

    10/24/25 8:56:02 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kodiak Sciences upgraded by Barclays with a new price target

    Barclays upgraded Kodiak Sciences from Underweight to Equal Weight and set a new price target of $17.00

    9/25/25 8:23:23 AM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    SEC Filings

    View All

    SEC Form 10-K filed by Verrica Pharmaceuticals Inc.

    10-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    3/11/26 8:11:55 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)

    3/11/26 8:08:37 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14A filed by Marker Therapeutics Inc.

    PRE 14A - Marker Therapeutics, Inc. (0001094038) (Filer)

    3/10/26 4:59:15 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ZYNRELEF KIT issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-18) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 11/21/2024. Application Category: NDA, Application Number: 211988, Application Classification: Labeling

    11/22/24 4:36:11 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for APONVIE issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling

    3/11/24 4:38:31 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for CINVANTI issued to HERON THERAPS INC

    Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling

    3/11/24 4:38:29 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    – YCANTH® net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when compared to 2024 – – Company earned $35.6 million in total revenue in 2025, up from $7.6 million in the prior year – – YCANTH dispensed applicator units grew 99% to 51,296 in 2025 versus 25,773 units in 2024 – Company is advancing VP-315, its novel oncolytic peptide, toward a Phase 3 program for basal cell carcinoma in 2026, further analysis supports abscopal effects and tumor size reduction in untreated lesions – – First patient dosed in the first Phase 3 study of YCANTH for the treatment of common warts in December 2025, and Company expects to initiate

    3/11/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

    SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported late breaking echocardiography results from its Phase III clinical trial for ischemic heart failure of reduced ejection fraction (HFrEF), which affects millions of patients in the United States.    The clinical results were presented by Dr. Amish Raval, M.D., Professor of Medicine at University of Wisconsin School of Medicine and Public Health and CardiAMP HF Trial National Co-Principal Investigator, in the late breaking clinical trial oral presentation session of the Technology

    3/3/26 8:00:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Kramer Robin

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/11/26 9:18:25 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Chief Business Officer Kyme Pierre

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/11/26 9:18:19 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, Finance, and PFO House David Duane

    4 - Armata Pharmaceuticals, Inc. (0000921114) (Issuer)

    3/11/26 9:17:29 PM ET
    $ARMP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Financials

    Live finance-specific insights

    View All

    Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

    WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di

    3/5/26 8:00:00 AM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

    – ZYNRELEF® and APONVIE® Drive 65% Year-Over-Year Net Revenue Growth in Acute Care Franchise– Achieved $154.9 Million in 2025 Net Revenue– Issues Full-Year 2026 Net Revenue Guidance of $173 to $183 Million and Adjusted EBITDA of $10 to $20 Million CARY, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and twelve months ended December 31, 2025, and highlighted recent corporate updates. "As demonstrated in today's release, we are entering 2026 with exceptional momentum. The fourth quarter delivered the strongest results in the history of He

    2/26/26 8:00:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026

    CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, February 26, 2026, at 8:30 a.m. ET to report fourth quarter and full year 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available

    2/17/26 8:30:00 AM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Leadership Updates

    Live Leadership Updates

    View All

    BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

    SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the appointment of Farhan Shahab as Vice President of Quality. Mr. Shahab brings over 25 years of experience to BioCardia in similar executive roles. Mr. Shahab joins BioCardia from Welldoc (a digital health company focused on chronic disease management), where he served as Vice President of Quality and Regulatory. Prior to that, he served as Senior Director of Regulatory Affairs and Quality Assurance at Intuity Medical (a blood glucose monitoring device company), and as Dir

    11/24/25 8:15:00 AM ET
    $BCDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

    HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company's Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director with more than 30 years of global leadership spanning R&D, clinical trials, regulatory approvals, commercialization, and corporate strategy across multiple therapeutic modalities and in

    11/5/25 7:30:00 AM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors

    CARY, N.C., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the appointment of Thomas Cusack to its Board of Directors. Mr. Cusack has extensive experience in matters related to corporate finance, investment management, and corporate governance. Mr. Cusack was appointed to the Board pursuant to the Cooperation Agreement entered into between the Company and Rubric Capital Management LP, dated as of August 8, 2025. Mr. Cusack was appointed as a director of Heron as of October 27, 2025.  Mr. Cusack has more than 20 years of experience in investment management and corporate finance. 

    10/29/25 5:58:14 PM ET
    $HRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ARMP
    $BCDA
    $BIOC
    $ETAO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Verrica Pharmaceuticals Inc.

    SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    11/26/24 4:15:26 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.

    SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)

    11/14/24 3:34:00 PM ET
    $NRBO
    Biotechnology: Pharmaceutical Preparations
    Health Care